Virax Biolabs Group (VRAX) Competitors $0.79 0.00 (-0.52%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. CARM, CYCC, NERV, PRPH, TXMD, BFRG, IMNN, ERNA, CSCI, and IXHLShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Carisma Therapeutics (CARM), Cyclacel Pharmaceuticals (CYCC), Minerva Neurosciences (NERV), ProPhase Labs (PRPH), TherapeuticsMD (TXMD), Bullfrog AI (BFRG), Imunon (IMNN), Ernexa Therapeutics (ERNA), COSCIENS Biopharma (CSCI), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Carisma Therapeutics Cyclacel Pharmaceuticals Minerva Neurosciences ProPhase Labs TherapeuticsMD Bullfrog AI Imunon Ernexa Therapeutics COSCIENS Biopharma Incannex Healthcare Virax Biolabs Group (NASDAQ:VRAX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Which has higher valuation and earnings, VRAX or CARM? Virax Biolabs Group has higher earnings, but lower revenue than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$6.33K539.06-$6.06MN/AN/ACarisma Therapeutics$19.63M0.57-$60.48M-$1.56-0.17 Does the media favor VRAX or CARM? In the previous week, Carisma Therapeutics had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Carisma Therapeutics and 0 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score. Company Overall Sentiment Virax Biolabs Group Neutral Carisma Therapeutics Neutral Do insiders & institutionals have more ownership in VRAX or CARM? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate VRAX or CARM? Virax Biolabs Group presently has a consensus target price of $3.00, suggesting a potential upside of 281.68%. Carisma Therapeutics has a consensus target price of $1.93, suggesting a potential upside of 612.96%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71 Is VRAX or CARM more profitable? Virax Biolabs Group has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Carisma Therapeutics -254.28%N/A -137.38% Which has more risk and volatility, VRAX or CARM? Virax Biolabs Group has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. SummaryVirax Biolabs Group and Carisma Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.41M$2.98B$5.45B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E RatioN/A17.8930.0425.01Price / Sales539.06174.35377.6078.24Price / CashN/A41.8335.9458.58Price / Book0.627.278.135.68Net Income-$6.06M-$54.43M$3.25B$265.58M7 Day Performance-7.00%-0.07%1.09%2.50%1 Month Performance-9.28%5.07%2.75%1.87%1 Year Performance-27.22%10.31%28.40%24.05% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.1593 of 5 stars$0.79-0.5%$3.00+281.7%-27.6%$3.41M$6.33K0.005Gap UpCARMCarisma Therapeutics2.3633 of 5 stars$0.31+2.1%$1.93+512.3%-65.6%$13.14M$19.63M-0.2020Upcoming EarningsAnalyst ForecastCYCCCyclacel Pharmaceuticals0.5487 of 5 stars$8.21-16.3%N/A-97.5%$13.01M$14K-0.0114Upcoming EarningsHigh Trading VolumeNERVMinerva Neurosciences2.7719 of 5 stars$1.84-2.8%$5.00+171.7%-37.9%$12.86MN/A2.249PRPHProPhase Labs0.7886 of 5 stars$0.31-0.8%N/A-87.4%$12.78M$5.85M-0.24130Upcoming EarningsGap UpTXMDTherapeuticsMD0.6028 of 5 stars$1.10flatN/A-36.0%$12.73M$1.76M0.00420News CoverageUpcoming EarningsGap UpBFRGBullfrog AI0.9081 of 5 stars$1.34+3.1%N/A-44.9%$12.62M$60K-1.654IMNNImunon2.8786 of 5 stars$8.76-4.8%$232.50+2,554.1%-56.7%$12.45MN/A-0.4330Earnings ReportAnalyst RevisionGap UpERNAErnexa Therapeutics0.7084 of 5 stars$1.69+8.3%N/A-93.6%$12.45M$535K-0.2010Upcoming EarningsCSCICOSCIENS BiopharmaN/A$3.89-1.5%N/AN/A$12.25M$9.03M-0.6720Upcoming EarningsGap DownIXHLIncannex Healthcare0.5801 of 5 stars$0.41-8.6%N/A-77.1%$11.97M$98K-0.343News CoverageGap Up Related Companies and Tools Related Companies Carisma Therapeutics Competitors Cyclacel Pharmaceuticals Competitors Minerva Neurosciences Competitors ProPhase Labs Competitors TherapeuticsMD Competitors Bullfrog AI Competitors Imunon Competitors Ernexa Therapeutics Competitors COSCIENS Biopharma Competitors Incannex Healthcare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
